21. (amended) A composition as claimed in claim 1, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

22. (amended) A composition as claimed in claim 1, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 20% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 9% by weight and the outer polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

38. (amended) A composition as claimed in claim 36, wherein the plasticizer is present in an amount of from about 1% to about 20% by weight of dry polymer.

46. (amended) A process for the preparation of a pharmaceutical composition as claimed in claim 40, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

47. (amended) A process for the preparation of a pharmaceutical composition as claimed in claim 40, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.

Please add the following claims:

48. (new) A composition as claimed in claim 8, wherein the ratio of inner coating to outer coating is in the range of 1:0.3 to 1:5.

49. (new) A composition as claimed in claim 9, wherein the ratio of inner coating to outer coating is in the range of 1:0.3 to 1:5.

50. (new) A composition as claimed in claim 8, wherein the ratio of inner coating to outer coating is in the range of 1:0.5 to 1:4.

51. (new) A composition as claimed in claim 9, wherein the ratio of inner coating to outer coating is in the range of 1:0.5 to 1:4.

52. (new) A composition as claimed in claim 8, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

53. (new) A composition as claimed in claim 9, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner

polymeric coat comprises from about 1% to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

54. (new) A composition as claimed in claim 8, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 20% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 9% by weight and the outer polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

55. (new) A composition as claimed in claim 9, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 20% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 9% by weight and the outer polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

56. (new) A composition as claimed in claim 37, wherein the plasticizer is present in an amount of from about 1% to about 20% by weight of dry polymer.

57. (new) A composition as claimed in claim 56, wherein the plasticizer is triethyl citrate.

58. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 42, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

59. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 43, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

60. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 44, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

61. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 42, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.

62. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 43, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.

63. (new) A process for the preparation of a pharmaceutical composition as claimed in claim 4, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.